MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer.

摘要: Purpose Although the majority of patients with small cell lung cancer (SCLC) respond to initial chemotherapy, those disease progression at first response assessment (chemoresistance) have inferior outcomes. There is a need for predictive biomarkers aid investigators in designing future clinical trials that better stratify beyond standard and laboratory parameters identify new treatments this patient subpopulation. We hypothesized tumor microRNAs (miRNAs) could serve as chemoresistance prognostic survival SCLC treated systemic chemotherapy. Patients Methods samples annotated characteristics baseline comorbidities were available. miRNA microarray profiling was performed on diagnostic samples, analysis using XenoBase, data integration discovery tool. Confirmation top 16 candidates quantitative real-time polymerase chain reaction followed by analyses determine associated survival. Results miRNAs significantly miR-92a-2* ( p = 0.010), miR-147 0.018), miR-574-5p 0.039). By stepwise multivariate analysis, only gender contributed 0.023) 0.015), respectively. Baseline not or Conclusions Higher levels are decreased SCLC. Tumor may application screening risk de novo an effort design more tailored Further validation independent sample sets warranted.